Vaccine Enterprise & CollaborationBill Snow, Director

19 January 2013CHVI Afri-Can Forum

• Support a global approach to the challenge of HIV vaccine R&D that transcends individual funders, countries, researchers, and civil society

Enterprise in 2013: An Important Role to play

4

•Make best use of existing resources• Engage new funders and

resources

•Promote more efficient, faster ways for researchers and funders to share findings and avoid duplication of efforts•Convene scientific

community to share and discuss information & data

• Identify priority issues where collective effort is most effective• Engage current and new

partners in the field• Identify new, unmet

priority areas where additional resources are needed

Enterprise in 2012: An Important Role to PlaySupport a global approach to the challenge of HIV vaccine R&D that transcends individual funders, countries, researchers, and civil society

CoordinationCoordination CollaborationCollaboration Resource OptimizationResource Optimization

Knowledge SharingKnowledge Sharing

• Share info on strategies, current & planned activities, and budget

6

7

Priority Areas IdentifiedClinical trial site capacity Faster access to GMP product Access to and comparability of multiple adjuvants Industry expertiseAdvancement criteria for efficacy trials Tools to help funders’ maintain funding